Search hospitals > Michigan > Brighton
Saint Joseph Mercy Brighton
Claim this profileBrighton, Michigan 48114
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
223 reported clinical trials
7 medical researchers
Summary
Saint Joseph Mercy Brighton is a medical facility located in Brighton, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Saint Joseph Mercy Brighton is involved with conducting 223 clinical trials across 357 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Tareq Al BaghdadiSaint Joseph Mercy Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
70 reported clinical trials
127 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
45 reported clinical trials
99 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
34 reported clinical trials
94 drugs studied
Clinical Trials running at Saint Joseph Mercy Brighton
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Gastric Cancer
Prostate Cancer
Squamous Cell Carcinoma
Diffuse Large B-Cell Lymphoma
Gastroesophageal Junction Adenocarcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Joseph Mercy Brighton?
Saint Joseph Mercy Brighton is a medical facility located in Brighton, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Saint Joseph Mercy Brighton is involved with conducting 223 clinical trials across 357 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.